eMC - trusted, up to date and comprehensive information about medicines
Link to eMC medicine guides website
eMC homepage
Get Medicines Compendium UK app here

Novartis Consumer Health

Novartis Consumer Health UK Ltd, Park View, Riverside Way, Watchmoor Park, Camberley, Surrey, GU15 3YL, UK
Telephone: +44 (0)1276 687300
Fax: +44 (0)1276 687284
Medical Information Direct Line: +44 (0)1403 323 046
Medical Information e-mail: medicalaffairs.uk@novartis.com
Customer Care direct line: +44 (0)1276 687290
Medical Information Fax: +44 (0)1403 324 024

Before you contact this company: often several companies will market medicines with the same active ingredient. Please check that this is the correct company before contacting them. Why?

Summary of Product Characteristics last updated on the eMC: 13/12/2010
SPC Nicotinell Mint 2mg Lozenge

When a pharmaceutical company changes an SPC or PIL, a new version is published on the eMC. For each version, we show the dates it was published on the eMC and the reasons for change.

Updated on 13/12/2010 and displayed until Current
Reasons for adding or updating:
  • Change to section 1 -Name of the Medicinal product
  • Change to section 2 - Qualitative and quantitative composition
  • Change to section 4.1 - Therapeutic indications
  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.3 - Contraindications
  • Change to section 4.4 - Special warnings and precautions for Use
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 4.7 - Effects on Ability to Drive and Use Machines
  • Change to section 4.8 - Undesirable Effects
  • Change to section 4.9 - Overdose
  • Change to section 5.2 - Pharmacokinetic Properties
  • Change to section 6. 4 - Special Precautions for Storage
  • Change to section 9 - Date of first Authorisation/renewal of the Authorisation
  • Change to section 10 date of revision of the text
Date of revision of text on the SPC:   19-Nov-2010
Legal Category:   GSL
Black Triangle (CHM):   NO

Free-text change information supplied by the pharmaceutical company



Section 1

Addition of word ‘compressed’.

 

 

Section 2

Addition of excipient sodium (9.8 mg). Full list of excipients in section 6.1.

 

 

Section 4.1

Paragraph 1: Deletion of ‘Nicotinell treatment is indicated for the... ‘

 

New paragraph: The 2mg strength is used when severe withdrawal symptoms are experienced. 

 

Paragraph 2:  ‘Patient counselling support’ replaces ‘advice and support’.

 

Section 4.2

Clarification of high dose form as 2mg lozenge and low dose form as 1 mg lozenge.

 

Section 4.3

Change of wording from ‘Hypersensitivity to any excipients of the lozenge’ to ‘Hypersensitivity to nicotine or to any of the excipients’.

 

Section 4.4

Special warnings about excipients

Paragraph 2: E965 added after ‘contains aspartame’.

 

Paragraph 3: ‘a source of fructose’ has been added after ‘(E965).’

 

Paragraph 5: Word change from ‘have’ to ‘experience’.

 

Section 4.5

 ‘olanzapine’ moved from list in paragraph 3 to list in paragraph 2.

 

Section 4.7

Wording added:  ‘one should take into consideration that’ between ‘nevertheless’ and ‘smoking cessation’.

 

Section 4.8

Addition of sentence: Non dose-dependent adverse reactions are as follows: hypersensitivity, angioneurotic oedema and anaphylactic reactions.

 

Paragraph 3: Last sentence changed from :

‘Those with a tendency to indigestion may suffer initially from slight dyspepsia or heartburn.’ to ‘Those who are prone to indigestion may suffer initially from minor degrees of dyspepsia or heartburn; ‘

 

Addition of paragraph: ‘Increased frequency of aphthous ulcer may occur after abstinence from smoking.’

 

Addition of paragraph:  Adverse reactions are listed below, by system organ class and frequency. Frequencies are defined as: very common (³1/10), common (³1/100 to <1/10), uncommon (³1/1,000 to <1/100), rare (³1/10,000, <1/1,000) or very rare (<1/10,000).

 

Section 4.9

Treatment of overdosage: ‘Treatment of overdose should be immediate as symptoms may develop rapidly’ replaces ‘Following overdose, symptoms may be rapid particularly in children’.

 

Section 5.2

Paragraph 3 :  (2-)3 1/kg changed to 2-3 1/kg.

 

Section 6.4

Words deleted: ‘Store in the original package’.

 

Section 9

Dates changed from 31 July 2002 / 2 April 2004 to Date of first authorisation: 31 July 2002. Date of last renewal: 16 December 2008.

 

Section 10

Date changed from 10 January 2008 to 19 November 2010.

Updated on 03/04/2008 and displayed until 13/12/2010
Reasons for adding or updating:
  • Change to section 2 - Qualitative and quantitative composition
  • Change to section 3 - Pharmaceutical form
  • Change to section 4.1 - Therapeutic indications
  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.3 - Contraindications
  • Change to section 4.4 - Special warnings and precautions for Use
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 4.6 - Pregnancy and Lactation
  • Change to section 4.7 - Effects on Ability to Drive and Use Machines
  • Change to section 4.8 - Undesirable Effects
  • Change to section 5.1 - Pharmacodynamic Properties
  • Change to section 5.3 - Preclinical Safety Data
  • Change to section 6.1 - List of Excipients
  • Change to section 6. 5 - Nature and Contents of Container
  • Change to section 9 - Date of first Authorisation/renewal of the Authorisation
  • Change to section 10 date of revision of the text
Date of revision of text on the SPC:   01/2008
Legal Category:   GSL
Black Triangle (CHM):   NO

Free-text change information supplied by the pharmaceutical company

Section 2: addition of excipient quantities

Section 3: addition of “compressed”

Section 4.1: “ re-word” of indication

Section 4.2 : “re-wording” and addition of optimal dosage form table

Section 4.3 : Cardiovascular related contraindications moved to section 4.4

Section 4.4 : Previous cardiovascular contraindications moved to precautions. Addition of sub heading “Special warnings about excipients”

Section 4.5: section changed to separate out actual drug interactions and interactions related to smoking cessation

Section 4.6: minor re-word

Section  4.7: minor re-word and addition of statement re smoking cessation causing behavioural changes

Section 4.8: addition of Rare -Immune system disorders : hypersensitivity, angioneurotic oedema, anaphylactic reactions

Section 5.1: additional information given re nicotine

Section 5.3: re-worded

Section 6.1: E Nos added

Section 6.5: additional pack sizes 72, 144 added
Sections 9 & 10: dates changed
Updated on 28/09/2007 and displayed until 03/04/2008
Reasons for adding or updating:
  • Addition of separate SPCs covering individual presentations

Active Ingredients/Generics

 
   nicotine bitartrate dihydrate